Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2012
11/15/2012US20120288528 Mono-and disaccharide derivatives
11/15/2012US20120288526 Dna sequence and preparation of grass pollen allergen phl p4 by recombinant methods
11/15/2012US20120288504 Antagonists of il-6 to prevent or treat thrombosis
11/15/2012US20120288501 Substituted benzazoles and methods of their use as inhibitors of raf kinase
11/15/2012US20120288495 Therapeutic compositions and methods
11/15/2012US20120288492 NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS
11/15/2012US20120288491 Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
11/15/2012US20120288489 Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
11/15/2012US20120288487 Biodegradable paox polymer particle with cationic property
11/15/2012US20120288486 Method for Ameliorating or Preventing Arrhythmic Risk Associated with Cardiomyopathy
11/15/2012US20120288485 Use of jasmone for modulating melatonin production and calcification of the pineal gland
11/15/2012US20120288482 Therapeutic agent (y-39983) for corneal endothelial dysfunction
11/15/2012US20120288476 Structure and use of 5' phosphate oligonucleotides
11/15/2012US20120288472 Regulation of t cell-mediated immunity by tryptophan
11/15/2012US20120288471 Amine Condensation Polymers as Phosphate Sequestrants
11/15/2012US20120288319 Lip gloss
11/15/2012DE202012103733U1 Zusammensetzung zur nutritiven Ergänzung oder Behandlung bei Herpes Composition for nutritional supplement or treatment for herpes
11/15/2012CA2848173A1 Ceramide anionic liposome compositions
11/15/2012CA2843324A1 Compounds and pharmaceutical compositions for the treatment of viral infections
11/15/2012CA2839309A1 Anxiolytic effect of pterostilbene
11/15/2012CA2839264A1 Formulations of phospholipid comprising omega fatty acids
11/15/2012CA2835876A1 Crystalline salts of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same
11/15/2012CA2835874A1 A topical formulation for treatment of hyperkeratotic skin
11/15/2012CA2835761A1 Composition for modified release comprising ranolazine
11/15/2012CA2835705A1 Thiazole compounds, methods for preparation and use thereof
11/15/2012CA2835704A1 L-proline and citric acid co-crystals of (2s,3r,4r,5s,6r)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl) methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
11/15/2012CA2835688A1 Hepatitis c virus inhibitors
11/15/2012CA2835610A1 Proteostasis regulators
11/15/2012CA2835595A1 Non-aqueous patch
11/15/2012CA2835576A1 Protein-active agent conjugates and method for preparing the same
11/15/2012CA2835568A1 Methods of modulating micrornas in the treatment of pulmonary arterial hypertension
11/15/2012CA2835498A1 Biotechnological sulphated chondroitin sulphate at position 4 or 6 on the same polysaccharide chain, and process for the preparation thereof
11/15/2012CA2835492A1 Novel pharmaceutical formulation
11/15/2012CA2835478A1 Substituted indazole derivatives active as kinase inhibitors
11/15/2012CA2835450A1 Methods for preparing naphthyridines
11/15/2012CA2835422A1 Spiro-oxindole mdm2 antagonists
11/15/2012CA2835343A1 Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories
11/15/2012CA2835332A1 Polymorph of linagliptin benzoate
11/15/2012CA2835330A1 Sustained release paracetamol formulations
11/15/2012CA2835325A1 Compositions and methods for the prevention of esophageal cancer
11/15/2012CA2835321A1 Compounds for use in the treatment of feline retroviral infections
11/15/2012CA2835286A1 Carbonic anhydrase targeting agents and methods of using same
11/15/2012CA2835279A1 Combinations of trospium and salivary stimulants for the treatment of overactive bladder
11/15/2012CA2835277A1 Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
11/15/2012CA2835261A1 Partially saturated tricyclic compounds and methods of making and using same
11/15/2012CA2835209A1 Tricyclic pyrazole sulfonamide compounds and methods of making and using same
11/15/2012CA2835197A1 Treatment of polycystic disease
11/15/2012CA2835195A1 Tricyclic sulfonamide compounds and methods of making and using same
11/15/2012CA2834903A1 Substituted imidazopyridines and the use thereof
11/15/2012CA2834901A1 Substituted imidazopyridines and imidazopyridazines and the use thereof
11/15/2012CA2834828A1 Small molecule inhibitors of trpa1
11/15/2012CA2834745A1 Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
11/15/2012CA2834712A1 Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
11/15/2012CA2834621A1 Par1 inhibitors for use in the treatment or prevention of paramyxoviridae infections
11/15/2012CA2834604A1 Aminopyrimidines as syk inhibitors
11/15/2012CA2834438A1 Treatment of mastitis
11/15/2012CA2833914A1 Methods for the treatment and diagnostic of pulmonary arterial hypertension
11/15/2012CA2831351A1 Use of a2b adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
11/15/2012CA2829039A1 Effective amounts of (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods thereof
11/15/2012CA2828269A1 Triazolopyridine compounds as pim kinase inhibitors
11/15/2012CA2827642A1 Compounds and methods of treating diabetes
11/15/2012CA2817211A1 Hydroxamic acid derivatives and their use in the treatment of bacterial infections
11/14/2012EP2522672A1 Oxidized phospholipids
11/14/2012EP2522671A2 Modulators of 5-HT receptors and methods of use thereof
11/14/2012EP2522670A1 Heterocyclic CRF receptor antagonists
11/14/2012EP2522669A1 3-Spirocyclic indolyl derivatives useful as ORL-1 receptor modulators
11/14/2012EP2522668A1 Morphinan compounds
11/14/2012EP2522667A1 Morphinan compounds
11/14/2012EP2522665A1 Crystalline sodium salt of an HIV integrase inhibitor
11/14/2012EP2522664A1 Piperidine derivatives as NK1 antagonists
11/14/2012EP2522659A2 Modulators of ATP-binding cassette transporters
11/14/2012EP2522657A1 Indole derivative
11/14/2012EP2522654A2 Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient
11/14/2012EP2522653A2 Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient
11/14/2012EP2522647A1 Process of separating chiral isomers of chroman compounds and their derivatives and precursors
11/14/2012EP2522397A1 Combination therapies using HDAC inhibitors
11/14/2012EP2522396A1 Combination therapies using HDAC inhibitors
11/14/2012EP2522395A1 Combination therapies using HDAC inhibitors
11/14/2012EP2522394A2 Substituted phosphonates and their use decreasing amyloid aggregates
11/14/2012EP2522365A1 Compositions comprising azelastine and methods of use thereof
11/14/2012EP2522357A1 Treatment and/or prevention of inflammation and cutaneous photodamage and photoprotection of the skin with a water-soluble extract from plant of solanum genus
11/14/2012EP2522354A1 Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins
11/14/2012EP2522353A1 Cerebral nerve cell neogenesis agent
11/14/2012EP2522352A1 Methods for cancer therapy and stem cell modulation
11/14/2012EP2522351A1 Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling
11/14/2012EP2522350A1 Use of the active ingredient combination of a 1-diethylaminoethyl-3-chinoxalin-2-on derivative and an oxysterol for breaking resistance in the treatment of cancer and strengthening the immune system against cancer, bacterial and viral diseases, autoimmune diseases, increased stress and environmental influences
11/14/2012EP2522349A1 Water-Soluble Anionic Bacteriochlorophyll Derivatives and their Uses
11/14/2012EP2522348A1 Atrovastatin-containing coated preparation
11/14/2012EP2522347A1 Flavonols and procyanidins for inducing peripheral blood vessel vasodilation
11/14/2012EP2522346A1 Agent combinations of Hesperidin for treating sleep disorders
11/14/2012EP2522345A1 Methods for treating and preventing mucositis
11/14/2012EP2522344A1 Formulations of Low Dose Diclofenac and Beta-Cyclodextrin
11/14/2012EP2522343A1 Formulations of Low Dose Diclofenac and Beta-Cyclodextrin
11/14/2012EP2522342A1 A topical formulation for treatment of hyperkeratotic skin
11/14/2012EP2522341A1 Pharmaceutical compositions comprising Neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers
11/14/2012EP2522340A1 Method of using a thiazole derivative
11/14/2012EP2522338A2 Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy
11/14/2012EP2522223A1 Combined disinfection and decontamination agent having increased effectivity
11/14/2012EP2521786A2 Compositions and methods for vaccinating against hsv-2
11/14/2012EP2521785A2 Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
1 ... 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 ... 7860